NOSO-502
Description: NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.
Mode of Action (MoA): Inhibition bacterial ribosome
BVL-GSK098
Description: Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line tuberculosis treatments.
Mode of Action (MoA): Transcriptional modulator
Gepotidacin tissue distribution
Description: Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.
Mode of Action (MoA): Topoisomerase type II inhibitor
ERA4TB-01
Description: Molecule targeting cholesterol catabolism of mycobacteria.
Mode of Action (MoA): Cholesterol catabolism of mycobacteria
ERA4TB-02
Description: Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.
Mode of Action (MoA): Mycobacterium tuberculosis tryptophan synthase
ERA4TB-03
Description: Compounds targeting energy metabolism (electron chain transport).
Mode of Action (MoA): Energy metabolism
ERA4TB-04
Description: Compound targeting lysine transfer RNA synthetase, which is an essential gene as assessed by transposon mutagenesis.
Mode of Action: Lysine transfer RNA synthase
ERA4TB-06
Description: Mycobacterial membrane protein Large 3 (Mmpl3) compounds with potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.
Mode of Action: Mmpl3
ERA4TB-09
Natural product analogs active against Mycobacterium tuberculosis.
ERA4TB-10
Description: Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).
Mode of Action (MoA): DprE1
BC1 back up
Description: Lead optimisation program on BC1 inhibitors.
Mode of Action (MoA): BC1
RespiriTB
Description: Mycothione reductase (Mtr) target exploration.
Mode of Action (MoA): Mtr
RespiriNTM
Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.